Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
IMG Launches First ‘Student Journey Scholarship’ for International Students in the U.S.
INDIANAPOLIS, July 1, 2025 /PRNewswire/ -- IMG (International Medical Group), an award-winning…
XTEND Reality Inc. Debuts New U.S. Headquarters and Drone Production Facility in Tampa, Driving Innovation and National Security
New facility strengthens America's domestic drone production capacity while bringing high-tech jobs…